📊 BRSYF Key Takeaways
Is Brainsway Ltd. (BRSYF) a Good Investment?
Unable to provide meaningful fundamental analysis due to complete absence of financial data. The company's SEC filings are either unavailable or not properly filed with EDGAR. Without access to income statements, balance sheets, or cash flow data, any investment assessment would be speculative.
BrainsWay's fundamentals have improved meaningfully: revenue grew to $41.0M in 2024 from $31.8M in 2023, and first-half 2025 revenue rose another 27% year over year while gross margin stayed near 75%. The company has crossed into operating and net profitability, is generating strong operating cash flow, and carries a cash-rich balance sheet with limited financial leverage, though earnings quality still depends partly on finance income and large deferred revenue movements.
Why Buy Brainsway Ltd. Stock? BRSYF Key Strengths
- Medical device sector with potential market opportunity
- Listed on Nasdaq indicating compliance with exchange standards
- Operates in surgical/medical instruments industry with recurring revenue potential
- Revenue growth is strong and sustained, with 2024 revenue up about 29% and first-half 2025 up about 27% year over year
- Gross margin has remained high and stable at roughly 75% while the business moved from losses in 2023 to operating and net profit in 2024 and 2025
- Financial health is solid, with about $67.9M cash plus $10.1M short-term deposits at June 30, 2025 and strong liquidity relative to liabilities
BRSYF Stock Risks: Brainsway Ltd. Investment Risks
- No financial data available - cannot assess profitability, solvency, or operational efficiency
- Unclear filing status with SEC - potential regulatory or reporting concerns
- Inability to evaluate revenue trends, cash position, or debt obligations creates significant information risk
- Profitability is still early-stage and net income is meaningfully helped by finance income rather than purely operating leverage
- Operating cash flow in first-half 2025 benefited heavily from a $14.7M increase in deferred revenue, which may not repeat at the same level
- Customer concentration is material, with one customer representing 31% of first-half 2025 revenue and two customers representing 30% of 2024 revenue
Key Metrics to Watch
- SEC EDGAR filing status and completeness
- Revenue and gross margin trends once data becomes available
- Operating cash flow and working capital adequacy
- Operating margin excluding finance income
- Deferred revenue conversion and customer concentration
Brainsway Ltd. (BRSYF) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
BRSYF Profit Margin, ROE & Profitability Analysis
BRSYF vs Healthcare Sector: How Brainsway Ltd. Compares
How Brainsway Ltd. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Brainsway Ltd. Stock Overvalued? BRSYF Valuation Analysis 2026
Based on fundamental analysis, Brainsway Ltd. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Brainsway Ltd. Balance Sheet: BRSYF Debt, Cash & Liquidity
BRSYF Revenue Growth, EPS Growth & YoY Performance
BRSYF SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Brainsway Ltd. (CIK: 0001505065)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BRSYF
What is the AI rating for BRSYF?
Brainsway Ltd. (BRSYF) has a Combined AI Rating of BUY from Claude (HOLD) and ChatGPT (BUY) with 40% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BRSYF's key strengths?
Claude: Medical device sector with potential market opportunity. Listed on Nasdaq indicating compliance with exchange standards. ChatGPT: Revenue growth is strong and sustained, with 2024 revenue up about 29% and first-half 2025 up about 27% year over year. Gross margin has remained high and stable at roughly 75% while the business moved from losses in 2023 to operating and net profit in 2024 and 2025.
What are the risks of investing in BRSYF?
Claude: No financial data available - cannot assess profitability, solvency, or operational efficiency. Unclear filing status with SEC - potential regulatory or reporting concerns. ChatGPT: Profitability is still early-stage and net income is meaningfully helped by finance income rather than purely operating leverage. Operating cash flow in first-half 2025 benefited heavily from a $14.7M increase in deferred revenue, which may not repeat at the same level.
What is BRSYF's revenue and growth?
Brainsway Ltd. reported revenue of N/A.
Does BRSYF pay dividends?
Brainsway Ltd. does not currently pay dividends.
Where can I find BRSYF SEC filings?
Official SEC filings for Brainsway Ltd. (CIK: 0001505065) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BRSYF's EPS?
Brainsway Ltd. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BRSYF a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Brainsway Ltd. has a BUY rating with 40% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is BRSYF stock overvalued or undervalued?
Valuation metrics for BRSYF: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BRSYF stock in 2026?
Our dual AI analysis gives Brainsway Ltd. a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BRSYF's free cash flow?
Brainsway Ltd.'s operating cash flow is N/A, with capital expenditures of N/A.
How does BRSYF compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).